LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

30.26 -1.27

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

29.7

Макс.

30.28

Ключевые показатели

By Trading Economics

Доход

60M

20M

Продажи

3.3M

96M

Рентабельность продаж

21.227

Сотрудники

923

EBITDA

22M

-24M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+38.09% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

14 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

96M

1.9B

Предыдущая цена открытия

31.53

Предыдущая цена закрытия

30.26

Новостные настроения

By Acuity

50%

50%

168 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 нояб. 2025 г., 21:06 UTC

Главные движущие силы рынка

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8 нояб. 2025 г., 18:10 UTC

Отчет

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

8 нояб. 2025 г., 13:10 UTC

Приобретения, слияния, поглощения

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 нояб. 2025 г., 12:00 UTC

Отчет

Apple's iPhone Air Is a Marketing Win and a Sales Flop -- WSJ

8 нояб. 2025 г., 10:30 UTC

Отчет

Why Car Insurers Are Under Pressure to Cut Rates -- Heard on the Street -- WSJ

8 нояб. 2025 г., 03:50 UTC

Приобретения, слияния, поглощения

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 нояб. 2025 г., 03:41 UTC

Приобретения, слияния, поглощения

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 нояб. 2025 г., 03:07 UTC

Приобретения, слияния, поглощения

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 нояб. 2025 г., 22:36 UTC

Отчет

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 нояб. 2025 г., 22:22 UTC

Отчет

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 нояб. 2025 г., 22:03 UTC

Отчет

Constellation Software 3Q Rev $2.95B >CSU.T

7 нояб. 2025 г., 22:03 UTC

Отчет

Constellation Software 3Q Net $210M >CSU.T

7 нояб. 2025 г., 22:03 UTC

Отчет

Constellation Software 3Q EPS $9.89 >CSU.T

7 нояб. 2025 г., 21:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

7 нояб. 2025 г., 21:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

7 нояб. 2025 г., 20:59 UTC

Отчет

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 нояб. 2025 г., 20:26 UTC

Обсуждения рынка

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 нояб. 2025 г., 20:22 UTC

Отчет

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 нояб. 2025 г., 20:04 UTC

Обсуждения рынка

Oil Futures Close Choppy Week With Losses -- Market Talk

7 нояб. 2025 г., 19:34 UTC

Обсуждения рынка

Gold Posts Small Gain for Week -- Market Talk

7 нояб. 2025 г., 19:31 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 нояб. 2025 г., 19:17 UTC

Отчет

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 нояб. 2025 г., 19:09 UTC

Отчет

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 нояб. 2025 г., 19:08 UTC

Отчет

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 нояб. 2025 г., 18:31 UTC

Обсуждения рынка

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 нояб. 2025 г., 17:27 UTC

Обсуждения рынка

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 нояб. 2025 г., 17:20 UTC

Обсуждения рынка

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 нояб. 2025 г., 17:20 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

7 нояб. 2025 г., 17:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

7 нояб. 2025 г., 17:20 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

38.09% рост

Прогноз на 12 месяцев

Средняя 41.8 USD  38.09%

Максимум 50 USD

Минимум 36 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

168 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat